Author: sf-admin

OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks

Noctría Arrives to Own the Night

Owner 1win Rewards 1win CS2 Team With $100K Bonus After Team Spirit Upset

Finnable Introduces Structured Used Car Loan Solutions Through Paperless Processing

Finnable Introduces Structured Used Car Loan Solutions Through Paperless Processing

FDUSD 的发行方First Digital已与CSLM Digital Asset Acquisition Corp III签订最终业务合并协议，以投前股权估值计，该协议对First Digital的估值为2.5亿美元。该公司累计交易量已超过四万亿美元。交易完成后，合并后的公司预计将成为纳斯达克上市公司

FDUSD 的发行方First Digital已与CSLM Digital Asset Acquisition Corp III签订最终业务合并协议，以投前股权估值计，该协议对First Digital的估值为2.5亿美元。该公司累计交易量已超过四万亿美元。交易完成后，合并后的公司预计将成为纳斯达克上市公司

FDUSD(누적 거래량 4조 달러 이상 기록)를 운영하는 그룹 First Digital이 CSLM Digital Asset Acquisition Corp III와 First Digital의 가치를 투자 전 지분가치(pre-money equity) 기준 2억 5,000만 달러로 평가하는 사업결합 확정 계약을 체결했으며, 거래 종결 시 합병 후 통합법인은 나스닥 상장사가 될 것으로 예상됩니다

FDUSD(누적 거래량 4조 달러 이상 기록)를 운영하는 그룹 First Digital이 CSLM Digital Asset Acquisition Corp III와 First Digital의 가치를 투자 전 지분가치(pre-money equity) 기준 2억 5,000만 달러로 평가하는 사업결합 확정 계약을 체결했으며, 거래 종결 시 합병 후 통합법인은 나스닥 상장사가 될 것으로 예상됩니다

Vexillum Minerals Strengthens Executive Leadership as Company Advances Global Growth & Public Market Strategy

Platform converts images into rigged, animated 3D assets and connects with Blender, Unity, Unreal Engine, Godot and AI-assisted workflows

Platform converts images into rigged, animated 3D assets and connects with Blender, Unity, Unreal Engine, Godot and AI-assisted workflows

 Not for distribution to U.S. newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, into the United States

Recognition highlights Securonix’s long-term growth potential amid rising demand for governed AI and modern security operations 

First Digital, the group behind FDUSD, which has recorded more than $4 trillion in cumulative trading volume, has entered into a definitive business combination agreement with CSLM Digital Asset Acquisition Corp III valuing First Digital at $250 million on a pre-money equity basis; on closing, the post-combined company is expected to become a Nasdaq-listed company

First Digital, the group behind FDUSD, which has recorded more than $4 trillion in cumulative trading volume, has entered into a definitive business combination agreement with CSLM Digital Asset Acquisition Corp III valuing First Digital at $250 million on a pre-money equity basis; on closing, the post-combined company is expected to become a Nasdaq-listed company

Establishes One of the Permian Midland Basin’s Largest Integrated Natural Gas Gathering and Processing Platforms

Establishes One of the Permian Midland Basin's  Largest Integrated Natural Gas Gathering and Processing Platforms

Acquisition expands Constellation’s portfolio into an emerging, consumer-led demand space within the fast-growing RTD category

Acquisition expands Constellation's portfolio into an emerging, consumer-led demand space within the fast-growing RTD category

Completes Navitas’ high-power portfolio with Claros’ IVR technology, enabling vertical and embedded architectures and providing last step in power delivery to the core

Legend Senior Living acquires Ashton Commons in Wexford, PA, expanding its Pittsburgh presence with Independent Living, Personal Care and Memory Care.

Legend Senior Living acquires Ashton Commons in Wexford, PA, expanding its Pittsburgh presence with Independent Living, Personal Care and Memory Care.

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. 
 
“We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders.”
 
BioLife’s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen’s existing offering in this market. BioLife’s differentiated biopreservation media portfolio, led by CryoStor^®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships.
 
In connection with the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock.
 
Repligen intends to provide additional detail regarding the transaction’s expected impact on Repligen’s 2026 financial outlook in the upcoming third quarter 2026 earnings call.
 
Advisors
Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife.
 
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
 
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements regarding the expected benefits of the transaction and Repligen’s ability to recognize such benefits; the anticipated financial impact of the transaction on Repligen; expectations for Repligen’s performance following the transaction; and beliefs and expectations about the cell therapy industry, including its growth, and BioLife’s position as a highly-differentiated cell processing tool leader. Words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
 
Repligen Contact: 
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. 
 
“We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders.”
 
BioLife’s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen’s existing offering in this market. BioLife’s differentiated biopreservation media portfolio, led by CryoStor^®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships.
 
In connection with the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock.
 
Repligen intends to provide additional detail regarding the transaction’s expected impact on Repligen’s 2026 financial outlook in the upcoming third quarter 2026 earnings call.
 
Advisors
Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife.
 
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
 
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements regarding the expected benefits of the transaction and Repligen’s ability to recognize such benefits; the anticipated financial impact of the transaction on Repligen; expectations for Repligen’s performance following the transaction; and beliefs and expectations about the cell therapy industry, including its growth, and BioLife’s position as a highly-differentiated cell processing tool leader. Words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
 
Repligen Contact: 
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com

Capsoil® Technologies acquires Red Mesa Science & Refining